Orexigen Therapeutics, Inc. (OREX) Reports In-Line Q2 Loss of 21c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
BofA/Merrill Lynch Remains Bullish on Orexigen (OREX) Ahead of Sept PDUFA Amid Update; PT Trimmed to $10
August 7, 2014 3:38 PM EDTShares of Orexigen Therapeutics (NASDAQ: OREX) are modestly higher following encouraging comments from management about activities it is conducting ahead of the September 11thPDUFA for its weight loss drug NB32 (Contrave).
BofA/Merrill Lynch analyst Steve Byrne highlights that Orexigen has been working... More
